Skip to main content
. 2006 Jan 3;103(2):341–346. doi: 10.1073/pnas.0506618103

Fig. 4.

Fig. 4.

Multiple domains of gp78 are required to target itself and a heterologous ERAD substrate for degradation. (A-C) Cells were cotransfected with the indicated forms of gp78 together with CD3-δ and lysates analyzed by IB. (B and C) Cells were treated with cycloheximide (CHX), as indicated. (D) Graphic representation of CD3-δ levels from B and C (full length gp78 transfections only). Cue-m1,2 is the average of data shown in B and C. (E) Cells were cotransfected with TCR-α and GFP fusions of gp78 and treated with MG132 where indicated. (F) Cells transfected with CD3-δ and Mdm2 were cotransfected with Flag-tagged amino acids 574-643 of gp78 where indicated. In lanes 3 and 6, 2 μg of Ube2g2 plasmid was cotransfected; in lanes 4 and 7, 4 μg was used. MG132 treatment was for 8 h.